Skip to main content
Search
Search
    Quick Search anywhere
    Quick search in Citations
Advanced Search
Skip main navigationClose Drawer MenuOpen Drawer Menu
Previous article
Next article
Original Communication

No beneficial effects of resveratrol supplementation on atherogenic risk factors in patients with nonalcoholic fatty liver disease

Published Online:February 21, 2019https://doi.org/10.1024/0300-9831/a000528

Abstract

Abstract.Introduction: Cardiovascular disease (CVD) accounts as a major cause of mortality among patients with nonalcoholic fatty liver disease (NAFLD). Resveratrol, a natural polyphenol compound, is known for its antioxidant and antiatherogenic properties and is purported to be beneficial in decreasing CVD risk factors in NAFLD patients. Objectives: This study aimed to investigate the effects of resveratrol on atherogenic risk factors in patients with NAFLD.

Methods: This randomized, double-blind, placebo-controlled clinical trial was performed on 50 patients with NAFLD aged 20-60 years. Subjects were randomly assigned to receive a daily dose of 600 mg resveratrol (n = 25) or placebo (n = 25) for 12 wk. Serum liver enzymes, lipid profile and atherogenic indices, blood pressure and anthropometric values were assessed pre and post-treatment.

Results: Resveratrol supplementation reduced body weight (from 88.75 ± 11.41 to 87.54 ± 11.18 kg, P = 0.005) and BMI (from 31.00 ± 3.16 to 30.60 ± 3.26 kg/m², P = 0.01) significantly compared to the placebo group. A significant reduction in waist circumference was observed within resveratrol group (from 102.70 ± 7.68 to 101.39 ± 7.62 cm, P = 0.02). There were no significant changes in lipid profile (ox-LDL, ApoA1 and ApoB), serum atherogenic indices (LDL-C/HDL-C, ApoB/ApoA1, ox-LDL/ApoB, LDL-C/ox-LDL and AIP), liver enzymes (AST, ALT, ALP and GGT), hip circumference, waist-to-hip ratio and blood pressure in either group (P > 0.05 for all).

Conclusion: These findings indicated that resveratrol supplementation in dose and duration used in this study did not affect most of the CVD risk factors in NAFLD patients. Further studies are warranted to explain more effects of resveratrol on CVD complications of NAFLD.

Registration ID in IRCT: IRCT201511233664N16

References

  • 1 Alkhouri, N., Carter-Kent, C., Elias, M., & Feldstein, A.E. (2011) Atherogenic dyslipidemia and cardiovascular risk in children with nonalcoholic fatty liver disease 2. Clin. Lipidol. 6, 305–314. First citation in articleCrossref Medline, Google Scholar

  • 2 Musso, G., Gambino, R., Cassader, M., & Pagano, G. (2011) Meta-analysis: natural history of non-alcoholic fatty liver disease (NAFLD) and diagnostic accuracy of non-invasive tests for liver disease severity. Ann. Med. 43, 617–649. First citation in articleCrossref Medline, Google Scholar

  • 3 Targher, G., Rossini, M., & Lonardo, A. (2016) Evidence that non-alcoholic fatty liver disease and polycystic ovary syndrome are associated by necessity rather than chance: a novel hepato-ovarian axis? Endocrine. 51, 211–221. First citation in articleCrossref Medline, Google Scholar

  • 4 Alim, M., Sahay, R.K., Hafiz, N., Prabhakar, B., & Ibrahim, M. (2015) Cardiovascular disease risk assessment in diabetes and metabolic syndrome patients with and without non-alcoholic fatty liver disease. Int. J. Clin. Trials. 2, 91–96. First citation in articleCrossref, Google Scholar

  • 5 Adibi, A., Maleki, S., Adibi, P., Etminani, R., & Hovsepian, S. (2017) Prevalence of Nonalcoholic Fatty Liver Disease and its Related Metabolic Risk Factors in Isfahan, Iran. Adv. Biomed. Res. 6, 47. First citation in articleCrossref Medline, Google Scholar

  • 6 Pais, R., Barritt, A.S., Calmus, Y., Scatton, O., Runge, T., Lebray, P. et al. (2016) NAFLD and liver transplantation: Current burden and expected challenges. J. Hepatol. 65, 1245–1257. First citation in articleCrossref Medline, Google Scholar

  • 7 Lankarani, K.B., Ghaffarpasand, F., Mahmoodi, M., Lotfi, M., Zamiri, N., Heydar, S.T. et al. (2013) Non alcoholic fatty liverdisease in southern Iran: a population based study. Hepat. Mon. 13. First citation in articleGoogle Scholar

  • 8 Faghihzadeh, F., Adibi, P., & Hekmatdoost, A. (2015) The effects of resveratrol supplementation on cardiovascular risk factors in patients with non-alcoholic fatty liver disease: a randomised, double-blind, placebo-controlled study. Br. J. Nutr. 114, 796–803. First citation in articleCrossref Medline, Google Scholar

  • 9 Byrne, C.D., & Targher, G. (2015) NAFLD: a multisystem disease. J. Hepatol. 62, S47–S64. First citation in articleCrossref Medline, Google Scholar

  • 10 Lonardo, A., Sookoian, S., Chonchol, M., Loria, P., & Targher, G. (2013) Cardiovascular and systemic risk in nonalcoholic fatty liver disease-atherosclerosis as a major player in the natural course of NAFLD. Curr. Pharm. Des. 19, 5177–5192. First citation in articleCrossref Medline, Google Scholar

  • 11 Lonardo, A., Sookoian, S., Pirola, C.J., & Targher, G. (2016) Non-alcoholic fatty liver disease and risk of cardiovascular disease. Metabolism. 65, 1136–1150. First citation in articleCrossref Medline, Google Scholar

  • 12 Sanyal, A.J., Chalasani, N., Kowdley, K.V., McCullough, A., Diehl, A.M., Bass, N.M. et al. (2010) Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362, 1675–1685. First citation in articleCrossref Medline, Google Scholar

  • 13 Gonciarz, M., Gonciarz, Z., Bielanski, W., Mularczyk, A., Konturek, P., Brzozowski, T. et al. (2012) The effects of long-term melatonin treatment on plasma liver enzymes levels and plasma concentrations of lipids and melatonin in patients with nonalcoholic steatohepatitis: a pilot study. J. Physiol. Pharmacol. 63, 35. First citation in articleMedline, Google Scholar

  • 14 Chalasani, N., Younossi, Z., Lavine, J.E., Diehl, A.M., Brunt, E.M., Cusi, K. et al. (2012) The diagnosis and management of non‐alcoholic fatty liver disease: Practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association. Hepatology. 55, 2005–2023. First citation in articleCrossref Medline, Google Scholar

  • 15 Hassan, K., Bhalla, V., El Regal, M.E., & A-Kader, H.H. (2014) Nonalcoholic fatty liver disease: a comprehensive review of a growing epidemic. World J. Gastroenterol. 20, 12082–12101. First citation in articleCrossref Medline, Google Scholar

  • 16 Gossard, A.A., & Lindor, K.D. (2011) Current therapies for nonalcoholic fatty liver disease. Drugs. Today (Barc). 47, 915–922. First citation in articleCrossref Medline, Google Scholar

  • 17 Baran, B., & Akyüz, F. (2014) Non-alcoholic fatty liver disease: what has changed in the treatment since the beginning? World J. Gastroenterol. 20, 14219–14229. First citation in articleCrossref Medline, Google Scholar

  • 18 Baur, J.A. (2010) Resveratrol, sirtuins, and the promise of a DR mimetic. Mech. Ageing Dev. 131, 261–269. First citation in articleCrossref Medline, Google Scholar

  • 19 Tauriainen, E., Luostarinen, M., Martonen, E., Finckenberg, P., Kovalainen, M., Huotari, A. et al. (2011) Distinct effects of calorie restriction and resveratrol on diet-induced obesity and fatty liver formation. J. Nutr. Metab. 2011. First citation in articleCrossref Medline, Google Scholar

  • 20 Timmers, S., Konings, E., Bilet, L., Houtkooper, R.H., van de Weijer, T., Goossens, G.H. et al. (2011) Calorie restriction-like effects of 30 days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 14, 612–622. First citation in articleCrossref Medline, Google Scholar

  • 21 Dudekula, A., Rachakonda, V., Shaik, B., & Behari, J. (2014) Weight loss in nonalcoholic Fatty liver disease patients in an ambulatory care setting is largely unsuccessful but correlates with frequency of clinic visits. PloS One. 9, e111808. First citation in articleCrossref Medline, Google Scholar

  • 22 Pastor-Villaescusa, B., Rangel-Huerta, O.D., Aguilera, C.M., & Gil, A. (2015) A systematic review of the efficacy of bioactive compounds in cardiovascular disease: carbohydrates, active lipids and nitrogen compounds. Ann. Nutr. Metab. 66, 168–181. First citation in articleCrossref Medline, Google Scholar

  • 23 Tomé-Carneiro, J., Larrosa, M., González-Sarrías, A., Tomas-Barberan, F.A., Teresa Garcia-Conesa, M., & Carlos Espin, J. (2013) Resveratrol and clinical trials: the crossroad from in vitro studies to human evidence. Curr. Pharm. Des. 19, 6064–6093. First citation in articleCrossref Medline, Google Scholar

  • 24 Catalgol, B., Batirel, S., Taga, Y., & Ozer, N.K. (2012) Resveratrol: French paradox revisited. Front Pharmacol. 3 First citation in articleCrossref Medline, Google Scholar

  • 25 Chun-Fu, W., Jing-Yu, Y., Fang, W., & Xiao-Xiao, W. (2013) Resveratrol: botanical origin, pharmacological activity and applications. C. J. N. M. 11, 1–15. First citation in articleGoogle Scholar

  • 26 Tomé‐Carneiro, J., Gonzálvez, M., Larrosa, M., García‐Almagro, F.J., Avilés‐Plaza, F., Parra, S. et al. (2012) Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: A triple‐blind, 6‐month follow‐up, placebo‐controlled, randomized trial. Mol. Nutr. Food Res. 56, 810–821. First citation in articleCrossref Medline, Google Scholar

  • 27 Brasnyó, P., Molnár, G.A., Mohás, M., Markó, L., Laczy, B., Cseh, J. et al. (2011) Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br. J. Nutr. 106, 383–389. First citation in articleCrossref Medline, Google Scholar

  • 28 Gómez-Zorita, S., Fernández-Quintela, A., Macarulla, M., Aguirre, L., Hijona, E., Bujanda, L. et al. (2012) Resveratrol attenuates steatosis in obese Zucker rats by decreasing fatty acid availability and reducing oxidative stress. Br. J. Nutr. 107, 202–210. First citation in articleCrossref Medline, Google Scholar

  • 29 Kim, S., Jin, Y., Choi, Y., & Park, T. (2011) Resveratrol exerts anti-obesity effects via mechanisms involving down-regulation of adipogenic and inflammatory processes in mice. Biochem. Pharmacol. 81, 1343–1351. First citation in articleCrossref Medline, Google Scholar

  • 30 Aguirre, L., Portillo, M.P., Hijona, E., & Bujanda, L. (2014) Effects of resveratrol and other polyphenols in hepatic steatosis. World J. Gastroenterol. 20, 7366–7380. First citation in articleCrossref Medline, Google Scholar

  • 31 Andrade, J.M.O., Paraíso, A.F., de Oliveira, M.V.M., Martins, A.M.E., Neto, J.F., Guimarães, A.L.S. et al. (2014) Resveratrol attenuates hepatic steatosis in high-fat fed mice by decreasing lipogenesis and inflammation. Nutrition. 30, 915–919. First citation in articleCrossref Medline, Google Scholar

  • 32 Bremer, A.A. (2014) Resveratrol use in metabolic syndrome. Metab. Syndr. Relat. Disord. 12, 493–496. First citation in articleCrossref Medline, Google Scholar

  • 33 Weiner, G.M., & Ducruet, A.F. (2014) Resveratrol and pharmacological potentiation in ischemic stroke. Neurosurgery. 74, N17–N18. First citation in articleCrossref Medline, Google Scholar

  • 34 Raj, P., Louis, X.L., Thandapilly, S.J., Movahed, A., Zieroth, S., & Netticadan, T. (2014) Potential of resveratrol in the treatment of heart failure. Life Sci. 95, 63–71. First citation in articleCrossref Medline, Google Scholar

  • 35 Baczko, I., Liknes, D., Yang, W., Hamming, K.C., Searle, G., Jaeger, K. et al. (2014) Characterization of a novel multifunctional resveratrol derivative for the treatment of atrial fibrillation. Br. J. Pharmacol. 171, 92–106. First citation in articleCrossref Medline, Google Scholar

  • 36 Novelle, M.G., Wahl, D., Dieguez, C., Bernier, M., & Cabo, R.de. (2015) Resveratrol supplementation: where are we now and where should we go? Ageing Res. Rev. 21, 1–15. First citation in articleCrossref Medline, Google Scholar

  • 37 Chen, S., Zhao, X., Ran, L., Wan, J., Wang, X., Qin, Y. et al. (2015) Resveratrol improves insulin resistance, glucose and lipid metabolism in patients with non-alcoholic fatty liver disease: a randomized controlled trial. Dig. Liver Dis. 47, 226–232. First citation in articleCrossref Medline, Google Scholar

  • 38 Chachay, V.S., Macdonald, G.A., Martin, J.H., Whitehead, J.P., O’Moore–Sullivan, T.M., Lee, P. et al. (2014) Resveratrol does not benefit patients with nonalcoholic fatty liver disease. Clin. Gastroenterol. Hepatol. 12, 2092–2103. First citation in articleCrossref Medline, Google Scholar

  • 39 Heebøll, S., Kreuzfeldt, M., Hamilton-Dutoit, S., Kjær Poulsen, M., Stødkilde-Jørgensen, H., Møller, H.J. et al. (2016) Placebo-controlled, randomised clinical trial: high-dose resveratrol treatment for non-alcoholic fatty liver disease. Scand. J. Gastroenterol. 51, 456–464. First citation in articleCrossref Medline, Google Scholar

  • 40 Hall, A.R., Green, A.C., Luong, T.V., Burroughs, A.K., Wyatt, J., & Dhillon, A.P. (2014) The use of guideline images to improve histological estimation of hepatic steatosis. Liver Int. 34, 1414–1427. First citation in articleCrossref Medline, Google Scholar

  • 41 Moghaddam, M.B., Aghdam, F.B., Jafarabadi, M.A., Allahverdipour, H., Nikookheslat, S.D., & Safarpour, S. (2012) The Iranian Version of International Physical Activity Questionnaire (IPAQ) in Iran: content and construct validity, factor structure, internal consistency and stability. World. Appl. Sci. J. 18, 1073–1080. First citation in articleGoogle Scholar

  • 42 Friedewald, W.T., Levy, R.I., & Fredrickson, D.S. (1972) Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin. Chem. 18, 499–502. First citation in articleCrossref Medline, Google Scholar

  • 43 Liu, H., & Lu, H.y. (2014) Nonalcoholic fatty liver disease and cardiovascular disease. World J. Gastroenterol. 20, 8407–8415. First citation in articleCrossref Medline, Google Scholar

  • 44 Emokpae, M.A., Arogundade, A., & Adumanya, S.C. (2013) Use of atherogenic index of plasma in evaluating the potential cardioprotective effects of red wine consumption: Studies in Nigerian young adult volunteers. Biokemistri. 25, 118–123. First citation in articleGoogle Scholar

  • 45 Yang, M.H., Sung, J., & Gwak, Y. (2016) The associations between apolipoprotein B, A1, and the B/A1 ratio and nonalcoholic fatty liver disease in both normal-weight and overweight Korean population. J. Clin. Lipidol. 10, 289–298. First citation in articleCrossref Medline, Google Scholar

  • 46 Tang, P.C.T., Ng, Y.F., Ho, S., Gyda, M., & Chan, S.W. (2014) Resveratrol and cardiovascular health–promising therapeutic or hopeless illusion? Pharmacol. Res. 90, 88–115. First citation in articleCrossref Medline, Google Scholar

  • 47 Guo, R., Su, Y., Liu, B., Li, S., Zhou, S., & Xu, Y. (2014) Resveratrol suppresses oxidised low-density lipoprotein-induced macrophage apoptosis through inhibition of intracellular reactive oxygen species generation, LOX-1, and the p38 MAPK pathway. Cell. Physiol. Biochem. 34, 603–616. First citation in articleCrossref Medline, Google Scholar

  • 48 Das, M., & Das, D.K. (2010) Resveratrol and cardiovascular health. Mol. Aspects Med. 31, 503–512. First citation in articleCrossref Medline, Google Scholar

  • 49 Carrizzo, A., Forte, M., Damato, A., Trimarco, V., Salzano, F., Bartolo, M. et al. (2013) Antioxidant effects of resveratrol in cardiovascular, cerebral and metabolic diseases. Food Chem. Toxicol. 61, 215–226. First citation in articleCrossref Medline, Google Scholar

  • 50 Polimeni, L., Del Ben, M., Baratta, F., Perri, L., Albanese, F., Pastori, D. et al. (2015) Oxidative stress: New insights on the association of non-alcoholic fatty liver disease and atherosclerosis. World J. Hepatol. 7, 1325–1336. First citation in articleCrossref Medline, Google Scholar

  • 51 Gerszon, J., Rodacka, A., & Puchała, M. (2014) Antioxidant properties of resveratrol and its protective effects in neurodegenerative diseases. Adv. Cell. Biol. 4, 97–117. First citation in articleCrossref, Google Scholar

  • 52 Chen, Q.J., Lai, H.M., Chen, B.D., Li, X.M., Zhai, H., He, C.H. et al. (2016) Appropriate LDL-C-to-HDL-C ratio cutoffs for categorization of cardiovascular disease risk factors among Uygur adults in Xinjiang, China. Int. J. Environ. Res. Public Health. 13, 235. First citation in articleCrossref Medline, Google Scholar

  • 53 Călin, P., & Maria, P. (2012) Atherogenic risk quantification by using the atherogenic index of plasma (AIP) and cardiovascular risk calculator on hypertensive patients. Med Con. 8, 29–36. First citation in articleGoogle Scholar

  • 54 Kunutsor, S.K., Bakker, S.J., Kootstra-Ros, J.E., Blokzijl, H., Gansevoort, R.T., & Dullaart, R.P. (2015) Inverse linear associations between liver aminotransferases and incident cardiovascular disease risk: the PREVEND study. Atherosclerosis. 243, 138–147. First citation in articleCrossref Medline, Google Scholar

  • 55 Kunutsor, S.K., Apekey, T.A., & Khan, H. (2014) Liver enzymes and risk of cardiovascular disease in the general population: a meta-analysis of prospective cohort studies. Atherosclerosis. 236, 7–17. First citation in articleCrossref Medline, Google Scholar

  • 56 Goessling, W., Massaro, J.M., Vasan, R.S., D’Agostino, R.B., Ellison, R.C., & Fox, C.S. (2008) Aminotransferase levels and 20-year risk of metabolic syndrome, diabetes, and cardiovascular disease. Gastroenterology. 135, 1935–1944. First citation in articleCrossref Medline, Google Scholar

  • 57 Monami, M., Bardini, G., Lamanna, C., Pala, L., Cresci, B., Francesconi, P. et al. (2008) Liver enzymes and risk of diabetes and cardiovascular disease: results of the Firenze Bagno a Ripoli (FIBAR) study. Metabolism. 57, 387–392. First citation in articleCrossref Medline, Google Scholar

  • 58 Park, J.B., Kang, D.y., Yang, H.M., Cho, H.J., Park, K.W., Lee, H.Y. et al. (2012) Serum alkaline phosphatase is a predictor of mortality, myocardial infarction, or stent thrombosis after implantation of coronary drug-eluting stent. Eur. Heart J. 34, 920–931. First citation in articleCrossref Medline, Google Scholar

  • 59 Tynjälä, J., Kangastupa, P., Laatikainen, T., Aalto, M., & Niemela, O. (2012) Effect of age and gender on the relationship between alcohol consumption and serum GGT: time to recalibrate goals for normal ranges. Alcohol Alcohol. 47, 558–562. First citation in articleCrossref Medline, Google Scholar

  • 60 Bo, S., Ponzo, V., Ciccone, G., Evangelista, A., Saba, F., Goitre, I. et al. (2016) Six months of resveratrol supplementation has no measurable effect in type 2 diabetic patients. A randomized, double blind, placebo-controlled trial. Pharmacol. Res. 1, 896–905. First citation in articleCrossref, Google Scholar

  • 61 Movahed, A., Nabipour, I., Lieben Louis, X., Thandapilly, S.J., Yu, L., Kalantarhormozi, M. et al. (2016) The efficacy of resveratrol in controlling hypertension: study protocol for a randomized, crossover, double-blinded, placebo-controlled trial. Trials. 17, 296. First citation in articleCrossref Medline, Google Scholar

  • 62 Mansur, A.P., Roggerio, A., Goes, M.F., Avakian, S.D., Leal, D.P., Maranhão, R.C. et al. (2017) Serum concentrations and gene expression of sirtuin 1 in healthy and slightly overweight subjects after caloric restriction or resveratrol supplementation: A randomized trial. Int. J. Cardiol. 227, 788–794. First citation in articleCrossref Medline, Google Scholar

  • 63 Padmanabhan, P., Jahangeer, M.A., Singh, K., Pugazhenthi, B., Saravanan, T.R., Lalit, S.P. et al. (2013) Non-alcoholic fatty liver disease (NAFLD); Study from western region of Tamil Nadu. J.C.E.H. 3, S25–S26. First citation in articleGoogle Scholar

  • 64 Méndez-del Villar, M., González-Ortiz, M., Martínez-Abundis, E., Pérez-Rubio, K.G., & Lizárraga-Valdez, R. (2014) Effect of resveratrol administration on metabolic syndrome, insulin sensitivity, and insulin secretion. Metab. Syndr. Relat. Disord. 12, 497–502. First citation in articleCrossref Medline, Google Scholar

  • 65 Bode, L.M., Bunzel, D., Huch, M., Cho, G.S., Ruhland, D., Bunzel, M. et al. (2013) In vivo and in vitro metabolism of trans-resveratrol by human gut microbiota. Am. J. Clin. Nutr. 97, 295–309. First citation in articleCrossref Medline, Google Scholar